Artemisinin-naphthoquine plus lower-dose primaquine to treat and prevent recurrence of Plasmodium vivax malaria: an open-label randomized and non-inferiority trial.

By day 365, the recurrence-free percentage had increased from 79.5% of the artemisinin-naphthoquine group in the published study [ 26 ] to 88.4% of ANPQ3 group in this study, with a difference of 8.8 percentage points (95% CI 0.3–7.3; P = 0.0508), showing marginal significance.

also in 5,069 other papers